ANI acquires approved ANDA for Flecainide Acetate tablets USP

Download PDF Copy

Reviewed

ANI PharmaceuticalsMar 5 2015

ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today announced that it has acquired the approved abbreviated new drug application ("ANDA") for Flecainide Acetate tablets USP 50mg, 100mg and 150mg, previously marketed by Teva Pharmaceuticals. According to IMS Health, the overall market for this product was approximately $39 million in 2014.

Arthur S. Przybyl, President and CEO of ANI Pharmaceuticals, stated, "This acquisition further expands our near-term generic pipeline. We intend to re-launch the product within the next 12 months. We are excited that this transaction further extends the ANI-Teva relationship."

ANI has forty-seven generic drug products under development addressing a total annual market size of approximately $3.0 billion, based on data from IMS Health.

Source:

ANI Pharmaceuticals

Posted in: Business / Finance | Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

New study reveals long road to seizure control for people with focal epilepsy

New treatment approach developed to prevent lupus nephritis

Mentavi study validates first fully digital diagnostic pathway for adult ADHD

WHO expands global network of trusted medical product regulators

University of Maine team develops sustainable method to cut drug production costs

Mushrooms deliver nutrition medicine and sustainability solutions in one package

COPD care pathways improve hospital outcomes and standardize treatment

CURE GABA-A and Grann Pharmaceuticals announce global partnership to advance rare neurological therapies

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.